|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Supplementary Table 1:** Descriptive statistics of study population. | | | | |
|  | **NAFLD**  **(n=107)** | **non-NAFLD**  **(n=66)** | |
| **Clinical Manifestation** | **Mean (SD)** | | **Mean (SD)** |
| **Sex, Male** | 75.70% | | 33.30% |
| **Age** | 14 (3) | | 13.4 (4.7) |
| **BMI z-score** | 2.24 (0.44) | | 0.4 (1.2) |
| **ALT (5-35 U/L)** | 112.6(69.4) | | 384.9 (687.1) |
| **Ceruloplasmin (20-43 mg/dL)** | 25.2 (5.8) | | 27.7 (7.8) |
| **Tissue copper (10-** ≤ **35 μg/g)** | 17.4 (8.7) | | 35.7(32.1) |
| Analysis of all eligible subjects (n=173) including those with tissue copper concentrations > 35μg/g. Subjects with Wilson’s disease, cholestatic liver diseases, and cirrhosis were excluded.  **BMI**, Body Mass Index; **ALT**, alanine aminotransferase. | | | |